布拉氏酵母菌联合柳氮磺吡啶栓对直肠型UC患者Baron内镜评分及肠黏膜屏障功能的影响  

Effect of Saccharomyces boulardii combined with salazosulfapyridine suppositories on Baron’s endoscopic score and intestinal mucosal barrier function in patients with rectal type UC

作　　者：唐闯 张鑫[1] 蔡涛 童霞 张婷[1] TANG Chuang;ZHANG Xin;CAI Tao;TONG Xia;ZHANG Tin(Department of Gastroenterology,West China Airport Hospital,Sichuan University(the First People’s Hospital of Shuangliu District,Chengdu),Chengdu,Sichuan,China,610200)

机构地区：[1]四川大学华西空港医院(成都市双流区第一人民医院)消化科,四川成都610200

出　　处：《分子诊断与治疗杂志》2023年第7期1256-1260,共5页Journal of Molecular Diagnostics and Therapy

基　　金：成都市医学科研课题立项项目(2022107)。

摘　　要：目的探讨布拉氏酵母菌联合柳氮磺吡啶栓对直肠型溃疡性结肠炎(UC)患者Baron内镜评分及肠黏膜屏障功能的影响。方法选取2020年2月至2022年2月于成都市双流区第一人民医院消化内科就诊治疗的100例UC患者,简单随机化分为两组,各50例。对照组给予磺胺类抗菌药,研究组在对照组的基础上给予布拉氏酵母菌,连续治疗2个月。比较两组治疗效果、临床症状缓解时间及黏膜愈合时间、Baron内镜评分、Sutherland疾病活动指数、肠道菌群、肠黏膜屏障功能、不良反应。结果研究组治疗总有效率92.00%高于对照组72.00%,差异有统计学意义(χ^(2)=6.775,P<0.05);研究组腹痛、便血、发热、腹泻缓解时间及黏膜愈合时间短于对照组,差异有统计学意义(t=7.519、9.176、8.533、5.411、11.203,P<0.05);治疗1个月后、2个月后研究组Baron内镜评分、Sutherland疾病活动指数低于对照组,差异有统计学意义(t=3.326、4.314,4.252、5.394,P<0.05);治疗1个月后、2个月后研究组肠杆菌低于对照组,双歧杆菌、乳酸杆菌高于对照组,差异有统计学意义(t=6.356、16.815,5.326、11.122,10.313、10.825,P<0.05);治疗1个月后、2个月后研究组血清ET、D⁃乳酸、DAO水平低于对照组,差异有统计学意义(t=7.016、7.276,3.126、3.798,5.483、11.222,P<0.05);两组不良反应发生率比较,差异无统计学意义(χ^(2)=0.000,P>0.05)。结论布拉氏酵母菌联合磺胺类抗菌药治疗UC疗效确切,有助于控制临床症状,降低Baron内镜评分,调节肠道菌群,恢复肠黏膜屏障功能。Objective To investigate the effects of Saccharomyces boulardii combined with sala⁃zosulfapyridine suppositories on Baron’s endoscopic score and intestinal mucosal barrier function in patients with rectal⁃type ulcerative colitis(UC).Methods 100 patients with UC who were treated in our Gastroenter⁃ology Department in the First People’s Hospital of Shuangliu District from February 2020 to February 2022 were selected and simply randomized into 2 groups of 50 patients each.The control group was given sulfon⁃amide antibacterial drugs,while the research group was treated with Saccharomyces boulardii based on the con⁃trol group,and all patients were treated continuously for 2 months.The treatment effects,time to clinical symptom relief and mucosal healing,Baron endoscopy score,Sutherland disease activity index,intestinal flo⁃ra,intestinal mucosal barrier function,and adverse effects were compared between the 2 groups.Results The total effective rate of treatment in the study group was 92.00%higher than that in the control group,72.00%,and the difference was statistically significant(χ^(2)=6.775,P<0.05).The time to relieve abdominal pain,blood in stool,fever,diarrhea and mucosal healing in the study group was shorter than that in the control group,and the difference was statistically significant(t=7.519,9.176,8.533,5.411,11.203,P<0.05).Baron's endoscopic score and Sutherland's disease activity index were lower in the study group than in the control group after 1 month and 2 months of treatment,and the differences were statistically significant(t=3.326,4.314,4.252,5.394,P<0.05).Enterobacteriaceae in the study group were lower than the control group after 1 month and 2 months of treatment,while Bifidobacterium and Lactobacillus were higher than the control group,with statistically significant differences(t=6.356,16.815,5.326,11.122,10.313,10.825,P<0.05).After 1 month and 2 months of treatment,The levels of serum ET,D⁃lactate and DAO in the study group were lower than those in the control group,and the di

关 键 词：溃疡性结肠炎 磺胺类抗菌药 布拉氏酵母菌 Baron内镜评分 内毒素 D⁃乳酸 二胺氧化酶 

分 类 号：R574.62[医药卫生—消化系统]